Trial · NCT01964378
Results by group96
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 96
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Average Amount of Daily Rescue Medication at the End of the Maintenance Period (Per Protocol Set) | Cebranopadol | 4.25 | Standard Error 1.7 | milligram(s)/24 hours | |
| Average Amount of Daily Rescue Medication at the End of the Maintenance Period (Per Protocol Set) | Morphine Prolonged Release | 8.92 | Standard Error 1.72 | milligram(s)/24 hours | |
| Average Amount of Daily Rescue Medication at the End of the Maintenance Period (Full Analysis Set) | Cebranopadol | 3.46 | Standard Error 1.71 | milligram(s)/24 hours | |
| Average Amount of Daily Rescue Medication at the End of the Maintenance Period (Full Analysis Set) | Morphine Prolonged Release | 10.94 | Standard Error 1.75 | milligram(s)/24 hours | |
| Proportion of Participants With Clinically Relevant Pain Reduction at the End of the Maintenance Period | Cebranopadol | Clinically relevant pain reduction (Yes) | 48 | Participants | |
| Proportion of Participants With Clinically Relevant Pain Reduction at the End of the Maintenance Period | Morphine Prolonged Release | Clinically relevant pain reduction (Yes) | 51 | Participants | |
| Proportion of Participants With Clinically Relevant Pain Reduction at the End of the Maintenance Period | Cebranopadol | Clinically relevant pain reduction (No) | 16 | Participants | |
| Proportion of Participants With Clinically Relevant Pain Reduction at the End of the Maintenance Period | Morphine Prolonged Release | Clinically relevant pain reduction (No) | 10 | Participants | |
| Change in Weekly Mean of the Daily Average Pain Intensity Score From Baseline | Cebranopadol | -3.4 | Standard Deviation 2.11 | units on a scale | |
| Change in Weekly Mean of the Daily Average Pain Intensity Score From Baseline | Morphine Prolonged Release | -3.2 | Standard Deviation 1.60 | units on a scale | |
| Response Rate to Treatment | Cebranopadol | Non-responder | 13 | Participants | |
| Response Rate to Treatment | Morphine Prolonged Release | Non-responder | 9 | Participants | |
| Response Rate to Treatment | Cebranopadol | >= 0% pain reduction | 51 | Participants | |
| Response Rate to Treatment | Morphine Prolonged Release | >= 0% pain reduction | 52 | Participants | |
| Response Rate to Treatment | Cebranopadol | >= 10% pain reduction | 50 | Participants | |
| Response Rate to Treatment | Morphine Prolonged Release | >= 10% pain reduction | 52 | Participants | |
| Response Rate to Treatment | Cebranopadol | >= 20% pain reduction | 44 | Participants | |
| Response Rate to Treatment | Morphine Prolonged Release | >= 20% pain reduction | 50 | Participants | |
| Response Rate to Treatment | Cebranopadol | >= 30% pain reduction | 39 | Participants | |
| Response Rate to Treatment | Morphine Prolonged Release | >= 30% pain reduction | 42 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01964378/results